Ibrutinib for the Management of Schnitzler Syndrome: A Novel Therapy for a Rare Condition

J Oncol Pract. 2018 Jun;14(6):387-388. doi: 10.1200/JOP.18.00050. Epub 2018 Mar 20.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenine / analogs & derivatives
  • Aged, 80 and over
  • Exanthema / pathology
  • Histocytochemistry
  • Humans
  • Male
  • Piperidines
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / administration & dosage
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Pyrimidines / administration & dosage
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use*
  • Schnitzler Syndrome / diagnosis
  • Schnitzler Syndrome / drug therapy*
  • Skin / pathology
  • Treatment Outcome

Substances

  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Adenine